Recordati Industria Chimica E Farmaceutica S.p.A.(OTC) RCDTF

Recordati S.p.A. is a global pharmaceutical company headquartered in Milan, Italy, specializing in the research, development, production, and sale of pharmaceuticals. The company operates in various segments, including Specialty and Primary Care, and Rare Diseases, providing innovative treatments for a range of medical conditions.

Products and Services

• Specialty pharmaceuticals for rare diseases and complex conditions
• Primary care medications for chronic diseases like hypertension
• Innovative treatments for various therapeutic areas, including oncology and endocrinology

Growth Outlook

• Revenue of €716 million in Q1 2026, showing strong demand for products
• Net income of €153 million in Q1 2026, reflecting effective cost management
• Continued investment in R&D, with €87 million allocated in Q1 2026

Financial Highlights

• Trailing twelve months (TTM) revenue of €2.7 billion, indicating robust growth
• Net profit margin of 17.8% TTM, showcasing operational efficiency
• Dividend yield of 2.6% TTM, appealing for income-focused investors

Recordati S.p.A. has established itself as a key player in the pharmaceutical industry, with a diverse portfolio of products addressing critical health needs. The company's focus on rare diseases and specialty pharmaceuticals positions it well for future growth, supported by a solid financial foundation. Recent quarterly results demonstrate strong revenue and net income, highlighting effective management and strategic investments in research and development. With a commitment to innovation and a growing market presence, Recordati S.p.A. presents an intriguing opportunity for potential investors.